Form 4: Sangamo Therapeutics Director Kenneth J. Hillan Reports Acquisition of Common Stock and Stock Options

Director Kenneth J. Hillan reports acquisition of 25,000 shares of common stock and 50,000 stock options in Sangamo Therapeutics.

Summary

• On June 4, 2024, Kenneth J. Hillan, a director of Sangamo Therapeutics, acquired 25,000 shares of common stock.
• These shares were obtained through the settlement of a restricted stock unit (RSU) grant.
• The RSU will fully vest on the earlier of June 4, 2025, or the day prior to the 2025 annual meeting of stockholders, contingent upon continuous service.
• Hillan also acquired 50,000 stock options with an exercise price of $0.5676 on the same date.
• The stock options are immediately exercisable, but unvested shares purchased under the option are subject to repurchase rights by the issuer upon cessation of continuous service.
• The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard compensation practices. The director's acquisition of shares and options suggests confidence, but it's a routine transaction.

Positives

• The acquisition of stock and options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions can be influenced by various factors, including personal investment strategies and company compensation plans.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's investment in the company.

Key Dates